Showing results (101-110 of 277) with videos related to

Sort By:
Pageof 28
Investigational New Drugs|August 21, 2008
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancerElaina M Gartner, Kent A Griffith, Quintin Pan, et al.
Breast Cancer Research and Treatment|September 28, 2005
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breastCelina G Kleer, Kent A Griffith, Michael S Sabel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 27, 2011
Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007Jennifer A Schlichting, Amr S Soliman, Catherine Schairer, et al.
Frontiers in Oncology|September 13, 2021
RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast CancersHannah G Abraham, Peter J Ulintz, Laura Goo, et al.
Breast Disease|November 27, 2010
Clinical and epidemiologic profile of breast cancer in TanzaniaAshley M Burson, Amr S Soliman, Twalib A Ngoma, et al.
RSC Medicinal Chemistry|February 28, 2022
Insights into the modular design of kinase inhibitors and application to Abl and AxlSameer Phadke, Lluis Lopez-Barcons, Nathalie Vandecan, et al.
Plos One|September 20, 2019
Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypesMegan A Altemus, Laura E Goo, Andrew C Little, et al.
JMIR Cancer|April 15, 2018
Development of a Web-based Family Intervention for BRCA Carriers and Their Biological Relatives: Acceptability, Feasibility, and Usability StudyMaria C Katapodi, Miyeon Jung, Ann M Schafenacker, et al.
Neoplasia (New York, N.Y.)|August 23, 2002
Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinomaKenneth L van Golen, LiWei Bao, George J Brewer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Phase II trial of tetrathiomolybdate in patients with advanced kidney cancerBruce G Redman, Peg Esper, Quintin Pan, et al.
Pageof 28